BRPI0915455A2 - ácido eprosartan, composição farmacêutica, formulação farmacêutica, e, uso de ácido eprosartan - Google Patents

ácido eprosartan, composição farmacêutica, formulação farmacêutica, e, uso de ácido eprosartan

Info

Publication number
BRPI0915455A2
BRPI0915455A2 BRPI0915455A BRPI0915455A BRPI0915455A2 BR PI0915455 A2 BRPI0915455 A2 BR PI0915455A2 BR PI0915455 A BRPI0915455 A BR PI0915455A BR PI0915455 A BRPI0915455 A BR PI0915455A BR PI0915455 A2 BRPI0915455 A2 BR PI0915455A2
Authority
BR
Brazil
Prior art keywords
eprosartan acid
pharmaceutical composition
eprosartan
acid
pharmaceutical
Prior art date
Application number
BRPI0915455A
Other languages
English (en)
Inventor
R Van Den Akker Cornelis
Bielenberg Gerhard-Wilhelm
M Van Der Hulst Marcellus
A J Link Paulus
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of BRPI0915455A2 publication Critical patent/BRPI0915455A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915455A 2008-07-11 2009-07-09 ácido eprosartan, composição farmacêutica, formulação farmacêutica, e, uso de ácido eprosartan BRPI0915455A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8006708P 2008-07-11 2008-07-11
EP08160211 2008-07-11
PCT/EP2009/058724 WO2010003996A1 (en) 2008-07-11 2009-07-09 Eprosartan compositions

Publications (1)

Publication Number Publication Date
BRPI0915455A2 true BRPI0915455A2 (pt) 2017-06-27

Family

ID=39731507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915455A BRPI0915455A2 (pt) 2008-07-11 2009-07-09 ácido eprosartan, composição farmacêutica, formulação farmacêutica, e, uso de ácido eprosartan

Country Status (21)

Country Link
US (2) US20100010062A1 (pt)
EP (1) EP2317987B1 (pt)
JP (1) JP2011527314A (pt)
KR (1) KR20110031226A (pt)
CN (1) CN102088961A (pt)
AR (1) AR072477A1 (pt)
AU (1) AU2009268044A1 (pt)
BR (1) BRPI0915455A2 (pt)
CA (1) CA2730008A1 (pt)
CO (1) CO6331424A2 (pt)
DO (1) DOP2011000011A (pt)
EA (1) EA201170182A1 (pt)
EC (1) ECSP10010701A (pt)
IL (1) IL210001A0 (pt)
MX (1) MX2011000349A (pt)
NZ (1) NZ589904A (pt)
PE (1) PE20110412A1 (pt)
TW (1) TW201006826A (pt)
UA (1) UA100434C2 (pt)
WO (1) WO2010003996A1 (pt)
ZA (1) ZA201100223B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5910311B2 (ja) * 2012-05-23 2016-04-27 ニプロ株式会社 医薬錠剤およびその製造方法
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业(广州)有限公司 一种乐卡地平和阿托伐他汀复方制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
HUP0004407A3 (en) * 1997-11-17 2002-03-28 Smithkline Beecham Corp Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
TR200100172T2 (tr) * 1998-07-20 2001-05-21 Smithkline Beecham Corporation Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
EP1694305B1 (en) * 2003-12-01 2019-10-16 Recordati Ireland Limited Pharmaceutical compositions comprising lercanidipine
JP2007526309A (ja) * 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US20070116762A1 (en) * 2005-11-07 2007-05-24 Wilson Edward S Compositions of stabilized ramipril in combination with another active agent

Also Published As

Publication number Publication date
EP2317987A1 (en) 2011-05-11
UA100434C2 (en) 2012-12-25
TW201006826A (en) 2010-02-16
EP2317987B1 (en) 2014-04-23
IL210001A0 (en) 2011-02-28
EA201170182A1 (ru) 2011-08-30
KR20110031226A (ko) 2011-03-24
WO2010003996A1 (en) 2010-01-14
ZA201100223B (en) 2011-10-26
AR072477A1 (es) 2010-09-01
PE20110412A1 (es) 2011-07-04
CA2730008A1 (en) 2010-01-14
ECSP10010701A (es) 2011-01-31
US20120302555A1 (en) 2012-11-29
NZ589904A (en) 2012-08-31
DOP2011000011A (es) 2011-01-31
CN102088961A (zh) 2011-06-08
MX2011000349A (es) 2011-02-22
CO6331424A2 (es) 2011-10-20
JP2011527314A (ja) 2011-10-27
US20100010062A1 (en) 2010-01-14
AU2009268044A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0820899A2 (pt) Formulação cosmética, e, uso da composição
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
BRPI0915137A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI0915136A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0914343A2 (pt) composição, produto, uso da composição e método
DK2300472T3 (da) Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]